Equities Analysts Set Expectations for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Zevra Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will post earnings of ($1.92) per share for the year, down from their previous forecast of ($1.74). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q4 2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS and FY2027 earnings at $1.86 EPS.

Several other analysts have also commented on ZVRA. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. JMP Securities assumed coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 price objective for the company. Guggenheim started coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a "buy" rating and a $20.00 price target for the company. Roth Mkm boosted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. Finally, Maxim Group upped their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $21.00.

Zevra Therapeutics Stock Up 4.5 %

Shares of ZVRA traded up $0.41 during midday trading on Friday, hitting $9.54. 436,051 shares of the company's stock traded hands, compared to its average volume of 549,674. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.62. The firm's fifty day moving average is $8.16 and its 200-day moving average is $6.60. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $509.25 million, a price-to-earnings ratio of -4.63 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the company posted ($0.40) EPS.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company's stock worth $9,883,000 after buying an additional 58,866 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics in the first quarter valued at about $64,000. Jacobs Levy Equity Management Inc. increased its holdings in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock valued at $201,000 after buying an additional 17,557 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Zevra Therapeutics by 10.7% in the second quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company's stock valued at $1,080,000 after buying an additional 21,231 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company's stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.